From what I read, this is what the FDA said about
Post# of 148110
CytoDyn shared results from the first instances of leronlimab treatment on critically ill Covid-19 patients in Intensive Care Units in New York—long before there was any clinical data that might provide a basis on which to question the drug’s potential to achieve authorization—an FDA employee commented to colleagues internally “Approval is OUT OF THE QUESTION!!!” and “I HATE THEM[,]”